Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Insulin Efsitora Alfa (LY3209590) vs Insulin Glargine in Adults with Type 2 Diabetes on Multiple Daily Injections
2021-005878-25Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Insulin efsitora alfa in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in HbA1c from baseline. Started Jun 2022; status: completed.
02
Drugs
Insulin efsitora alfa
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2021-005878-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005878-25.